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Objectives: Intraductual papillary mucinous neoplasms (IPMNs) are often multifocal and involve the
entire pancreas. Because of the morbidity associated with total pancreatectomy, surgeons will perform
segmental pancreatectomy, resecting only the most ‘threatening’ IPMN lesion(s). We sought to determine
whether the presence of residual IPMN following segmental pancreatectomy for non-invasive IPMN
increases the risk for subsequent development of invasive pancreatic cancer and decreases survival.
Methods: Data on patients undergoing segmental resection of non-invasive IPMN during the period
1991–2010 at a high-volume academic institution were prospectively accrued.
Results: Of 243 patients who underwent segmental resection for IPMN, 191 (79%) demonstrated
non-invasive pathology. Of these, 153 (80%) showed the absence and 38 (20%) the presence of residual
IPMN at the initial operation. Of the 38 patients with residual IPMN, eight had positive IPMN margins, 23
had radiographic evidence of IPMN, and seven had both. During a mean follow-up of 73 months, 31
(20%) of 153 patients without residual IPMN developed a new radiographic lesion consistent with IPMN
and, of these, three (10%) were found to represent invasive cancer. One (3%) of 38 patients with residual
IPMN developed invasive cancer. In summary, in 191 initially non-invasive cases of IPMN, four invasive
cancers (2%) developed during follow-up. The mean progression-free interval in these four patients was
54 months (range: 20–99 months).
Conclusions: Compared with patients undergoing complete operative IPMN clearance, patients with
residual IPMN after segmental pancreatectomy do not demonstrate increased risk for the development of
invasive disease or reduced survival. In patients without residual IPMN who later develop new IPMN, the
risk for invasive IPMN is increased.
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Introduction
Intraductal papillary mucinous neoplasm (IPMN) is a mucin-
producing lesion of the pancreatic ductal system with varying
degrees of malignant potential.1,2 Its malignant potential is
increased in patients with symptoms, including radiographic fea-
tures (e.g. intramural nodules, main pancreatic duct dilation),
and/or atypia on cytopathology. Such high-risk occurrences of
IPMN should be resected in fit patients. Historically, complete
surgical clearance of IPMN was thought to represent optimal
therapy. This principle, however, was based on very limited data.
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The surgical approach to IPMN in patients with high-risk lesions
continues to evolve.
Many cases of IPMN demonstrate multi-centric disease involv-
ing multiple, often non-contiguous, regions of the pancreatic
gland, which presents a dilemma.3 In such patients in whom sur-
gical resection is indicated, the surgeon may be confronted with
the need to choose between performing a segmental pancreatec-
tomy, leaving residual IPMN, or a total pancreatectomy with its
attendant considerable morbidity.4–6 A similar scenario may be
encountered intraoperatively. In performing a segmental pancre-
atectomy for IPMN, the surgeon may be confronted with a posi-
tive margin based on an intraoperative frozen section. The
existing literature supports the extension of the resection to a
negative margin in the setting of invasive or high-grade dysplastic
disease at the margin.7,8 The issue of whether to extend resection
for low-grade non-invasive IPMN at the margin is controversial.
Reasonable attempts to clear IPMN at the margin with additional
segmental resection are acceptable, particularly if the IPMN
involves the main pancreatic duct. The efficacy of extended or
even total pancreatic resection in an effort to clear a low-grade
IPMN at the margin when there is no gross evidence of main duct
dilation remains unclear. In light of this, operative strategy
in such patients has evolved from the complete surgical clearance
of IPMN to the selective removal of the most threatening
lesion(s). This practice of resection of selective lesion(s) may leave
residual IPMN in the pancreatic remnant and/or at the margin of
resection.
If the decision is made to leave lower-grade IPMN at themargin
or residual disease in the remnant pancreas, surveillance must
ensue. The most appropriate and effective surveillance strategy is
unknown.7–11 Unfortunately, the risk for progression to invasive
cancer and the timing of this process in patients with residual
IPMN following segmental pancreatectomy are unknown.
Whether the natural histories of patients with and without IPMN
left in the pancreatic remnant following resection differ is unclear.
Currently, surveillance strategies of patients with radiologically or
pathologically evident residual IPMN rely heavily on clinical
history, interval imaging and cytologic sampling. Changes in the
size, character or distribution of existing lesions, the development
of new or worsening symptoms, and the development of new cysts
or positive cytology in the remnant gland are commonly used as
indications for re-resection. These recommendations are based
largely on published data regarding the initial diagnosis and resec-
tion of IPMN.12 Ultimately, the issue of when to perform addi-
tional pancreatic resection is unclear.
Despite the complete clearance of IPMN at the time of seg-
mental pancreatectomy, invasive IPMN has been documented to
appear within the pancreatic remnant during follow-up. This
potential for the development of de novo invasive disease in a
patient in whom the removal of non-invasive IPMN by segmen-
tal pancreatectomy was considered to be complete commits both
the surgeon and patient to longterm surveillance strategies.
Further, the risk for and timeframe of the development of inva-
sive disease in a patient with remnant pancreatic tissue are
unknown, which leaves the interval and total duration of sur-
veillance arbitrary.
We sought to determine the risk and timeframe for the devel-
opment of invasive cancer following segmental pancreatectomy
for non-invasive IPMN. In particular, we sought to evaluate the
effects of residual IPMN (at the margin or radiologically evident)
in comparison with outcomes in patients in whom all visible
disease is cleared in the setting of segmental pancreatectomy. We
hypothesized that non-invasive IPMN at the margin of resection
or radiologically evident IPMN in the remnant pancreas following
resection increases the risk for subsequent development of inva-
sive cancer and decreases survival compared with that in patients
in whom no evidence of IPMN in the pancreatic remnant is seen.
Materials and methods
Patient selection
Data for this study were catalogued prospectively and reviewed
retrospectively in compliance with patient confidentiality proto-
cols as determined by the guidelines set forth by Indiana Uni-
versity School of Medicine’s Institutional Review Board. All
patients were referred to Indiana University Hospital for
treatment between September 1991 and January 2010. All
patients were diagnosed with IPMN based on surgical pathology
and underwent pancreaticoduodenectomy, distal pancreatec-
tomy, central pancreatectomy or excision/enucleation performed
by an experienced pancreatic surgeon at Indiana University
Hospital.
Analysis of these data revealed that 243 patients with IPMN
underwent a segmental pancreatectomy.Of these, 52 patients were
found to have invasive disease on initial surgical pathology and
were excluded from analysis. Patients who underwent total (or
near total) pancreatectomy as initial management surgery were
also excluded. Electronic medical records were queried for demo-
graphic, clinical, serologic, endoscopic, pathologic and radiologic
data. Additionally, patient survival and follow-up were deter-
mined using electronic medical records and the social security
death index registry.
Because patients with invasive carcinoma at first operation were
excluded, the phrase ‘IPMN recurrence’ was not used. Rather,
when documenting an invasive IPMN which developed after
initial surgery for a non-invasive IPMN, these lesions were
referred to as a progression to invasive cancer or de novo invasive
IPMN. Patients developing de novo invasive IPMN had docu-
mented invasive carcinoma by biopsy or invasive adenocarcinoma
as determined by radiographic findings and clinical course (e.g.
mass in the pancreas with hepatic metastases).
Pathologic analysis
All pathology was reviewed by staff pathologists at Indiana Uni-
versity Hospital. Surgical pathology was determined as consistent
with IPMNwhen it showed amucinous lesion within the pancreas
that communicated with the pancreatic ducts and lacked the
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ovarian stroma consistent with a mucinous cystic neoplasm.
Staging of the initial non-invasive IPMN defined it as low-grade
or high-grade. Low-grade IPMN encompassed either adenoma
(dilated pancreatic duct lined by mucinous epithelium, fulfilling
one or none of the criteria for low-grade dysplasia [also called
‘duct ectasia’]) or borderline/moderate (fulfilling one or none of
the following criteria: epithelial tufting; nuclear pseudostratifica-
tion; nuclear atypia, and mitotic figures [also called ‘borderline’])
dysplasia categories. High-grade dysplasia was characterized by
cribiform or solid growth usually associated with high-grade
nuclear atypia (also called ‘non-invasive intraductal carcinoma’ or
‘carcinoma in situ’).9 On cytopathology, criteria for cytologic
atypia included at least one of the following: increased nucle-
ar : cytoplasmic ratio; increased nuclear size; nuclear crowding,
and hyperchromasia.
Statistical analysis
Data analysis was carried out using GraphPad Prism 4.00 (Graph-
Pad Software, Inc., La Jolla, CA, USA) and Microsoft Excel 2007
(Microsoft, Inc., Redmond, WA, USA). Overall and progression-
free survival were evaluated using the Kaplan–Meier test and sta-
tistical differences were evaluated using the log-rank test. All
means and proportions were compared using either Student’s
t-test or Fisher’s exact test as appropriate. Statistical significance
was accepted at P < 0.05.
Results
During the study period, 243 patients underwent segmental pan-
createctomy for pathologically confirmed IPMN. Of these, 191
were found to have non-invasive pathology. The mean follow-up
for these patients was 66 months. These patients were separated
into two groups consisting of those with and those without evi-
dence of residual IPMN following initial resection. These groups
are compared according to type of operation performed, pathol-
ogy and demographics in Table 1. Of the 191 total patients
analysed, 153 (80%) had no residual disease in the pancreatic
remnant. These patients had a mean follow-up of 73 months.
Conversely, 38 (20%) patients were known at the time of initial
resection (based on preoperative imaging and/or intraoperative
pathology) to have IPMN in the pancreatic remnant (Fig. 1).
Specifically, 23 had preoperative radiographic evidence of
residual IPMN, eight had positive IPMN at the margin of resec-
tion, and seven had both positive margins and radiologic evi-
dence of IPMN in the pancreatic remnant (Table 2). The mean
follow-up in this group was 41 months. The overall 5-year
progression-free survival of patients known at the time of initial
resection to have IPMN in the pancreatic remnant was 88%,
compared with 83% in patients with no residual IPMN burden
(P > 0.05) (Fig. 2A). Of the 38 patients with known remnant
disease, only one (3%) developed invasive carcinoma (Patient D,
Table 3). This patient was initially found to have low-grade
IPMN at the margin of resection involving the main pancreatic
duct during his initial operation and was diagnosed with inva-
sive disease 36 months later. He was found to be unresectable at
re-operation as a result of the vascular involvement of invasive
cancer, but remains alive at 62 months after his initial operation
(26 months from the diagnosis of invasive cancer). Of 30
patients with positive radiographic evidence of disease, none
developed invasive carcinoma during follow-up. No decrease in
progression-free survival was noted in patients with radio-
graphic evidence of residual disease within the pancreatic
remnant compared with patients without evidence of residual
disease (Fig. 2B).








Patients, n 153 38 191 –
Mean follow-up, months 73 41 66 <0.001
Mean age, years 67 71 68 0.09
Gender, % male 47 54 49 NS
ASA grade, mean (range) 2.92 (2–3) 2.97 (2–4) 2.93 NS
Operation, n (%)
Pancreaticoduodenectomy 94 (61) 23 (61) 117 (61) NS
Distal pancreatectomy 45 (29) 12 (32) 57 (30) NS
Central pancreatectomy 5 (3) 2 (5) 7 (4) NS
Enucleation 9 (6) 1 (3) 10 (5) NS
IPMN grade, n (%) NS
Low grade 128 (84) 34 (89) 162 (85) NS
High grade 25 (16) 4 (11) 29 (15) NS
Mean size of initial lesion, cm 2.2 2.4 2.2 NS
ASA, American Society of Anesthesiologists; NS, not significant
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Of the 153 patients without evidence of disease in the remnant
gland, 31 (20%) developed a new lesion in the pancreatic remnant
according to surveillance imaging. One of these patients was
re-operated twice for two new lesions, resulting in a total of 32
lesions. No difference in 5-year progression-free survival was
noted between patients developing a new lesion during surveil-
lance (87%) and those with no evidence of a new lesion (82%) (P
> 0.05) (Fig. 3). Three (9%) of these 32 new lesions were eventu-
ally found to represent invasive cancer. The characteristics of these
lesions are outlined in Table 4. When encountered, invasive
disease was diagnosed at a mean of 60 months (range: 20–99
months) after operation compared with 33 months (range: 7–145
months) for new non-invasive lesions. Two patients had unresec-
table disease and died at 31 months and 132 months, respectively,
after initial operation. One patient underwent re-resection
(Patient A, Table 3) and was found to have microinvasive disease.
This patient developed an additional new lesion 36 months after
undergoing a second resection and submitted to a third resection
(completion pancreatectomy), which revealed low-grade IPMN;
this patient remains alive at 175 months of follow-up. Follow-up
was performed elsewhere for 29 of the 153 patients and therefore
no comment can be made on any changes in the pancreatic
remnant in this subgroup; however, these patients remain alive.
A total of 11 patients underwent re-resection. Two of these
patients each underwent two pancreatic re-resections, making a
total of 13 re-resections. The pathologic results of these
re-resections are summarized in Table 5. Five (38%) of these
lesions represented low-grade IPMN. Four (31%) of the
re-resections demonstrated no IPMN. Two (15%) of the
re-resections demonstrated invasive disease, and an additional two
(15%) procedures showed high-grade dysplasia. Fine needle aspi-
ration (FNA) was performed in 10 of the 13 cases prior to
re-resection. The results are summarized in Table 6. In both
patients who were found to have invasive disease, FNA results were
false-negative in that they failed to capture high-grade dysplasia or
invasive cytology.
In summary, four (2%) of all patients subjected to segmental
pancreatic resection for non-invasive IPMN progressed to inva-
sive cancer during follow-up. The clinicopathologic characteris-
tics of these patients are outlined briefly in Table 3. The mean
interval to the development of the invasive lesions was 54 months
(range: 20–99 months). Patient D, who was found to have low-
grade dysplasia at the margin, developed recurrent invasive
disease at 36 months. This was determined to be unresectable, but
the patient remains alive at 62 months after initial surgery. The
remaining three patients showed no residual pathologic or radio-
logic evidence of IPMN in the remnant following the initial pan-
creatic resection. All four of the patients eventually diagnosed
with invasive disease underwent preoperative FNA, but only one
(25%) of the FNA results – of an omental lesion – was positive for
high-grade dysplasia. It should be noted that three (75%) of these
patients were symptomatic, each with significant abdominal pain.
Table 2 Characteristics of 38 patients with residual intraductal
papillary mucinous neoplasm (IPMN)
Residual IPMN status n = 38 Progression
to invasive
cancer
Positive margin onlya, n (%) 8 (21) 1b
Radiographic lesion only, n (%) 23 (61) –
Positive margin and radiographic
lesiona, n (%)
7 (18) –
aAll positive margins were low grade






































Figure 1 Distribution of all patients included in this study, showing numbers of patients with residual disease and numbers of patients who
progressed to invasive cancer. IPMN, intraductal papillary mucinous neoplasm
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Discussion
The incidence, outcome and natural history of de novo invasive
IPMN after segmental pancreatectomy for non-invasive IPMN are
not known. Because of the multifocal nature of IPMN, at initial
resection pancreatic surgeons are often confronted with low-grade
IPMN at the resection margin, or radiographic findings showing a
residual IPMN burden in the pancreatic remnant. This may
provoke substantial anxiety in the patient and surgeon, and may
result in costly and burdensome surveillance strategies. Although
the appropriate surveillance protocol in these patients is vigor-
ously debated, typical surveillance involves cross-sectional
imaging at least annually.13,14 In addition, patients with lesions that
demonstrate changes in radiologic character often undergo
repeated invasive cytologic sampling with endoscopic ultrasound
(EUS) and FNA. Given the premalignant character of IPMN and
its predilection for progression to pancreatic cancer, we hypoth-
esized that residual IPMN following segmental pancreatectomy
for non-invasive IPMN would increase the risk for subsequent
development of invasive cancer and diminish survival compared
with no evidence of IPMN in the remnant gland. Our findings do
not support our initial hypothesis. Rather, they suggest that, in the
setting of resection for non-invasive IPMN, patients with residual
IPMN that is apparent either at the margin or as radiographically
identified lesions are not at increased risk for development of
de novo invasive adenocarcinoma and have longterm survival
similar to that of patients with pathologic and radiographic IPMN
clearance at initial resection.
An additional and unexpected result in our study was found in
the subgroup of patients without residual disease after their initial
pancreatic resection. In this subgroup, 32 new lesions developed,
three (9%) of which were eventually pathologically confirmed as
representing invasive disease. This figure of 9% represents a large
increase in the risk for development of invasive disease in patients
who have developed new radiographic lesions suspicious for
IPMN. However, 5-year survival from the initial operation in
these 32 patients with new lesions was not lower than that in
patients without new lesions. This is likely to reflect the small
number of deaths caused by de novo invasive lesions (n = 2), the
long interval to the development of these invasive lesions and the
indolent nature of some subtypes of invasive IPMN.15,16
Currently, the decision to perform re-resection in the setting of
IPMN is based primarily on radiologic changes in existing lesions,
the development of new lesions, cytologic findings of concern, or
symptoms of concern. In this series, 11 patients underwent
re-resection (n = 13 re-resections). Of the re-resections per-
formed, four (31%) yielded invasive cancer or high-grade dyspla-
sia and the remaining nine (69%) demonstrated either low-grade
IPMN or no IPMN at all. Positive cytology can give excellent
confirmatory information; however, negative test results are com-
plicated by the method’s inherent low sensitivity.17 In this study,
FNA results alone did not represent an effective indicator of which
patients harboured invasive pathology. Of the four patients found
to have either invasive or high-grade lesions on re-operation, none
demonstrated atypia on preoperative FNA of the IPMN. This
suggests that current strategies to identify and intervene in the
very small proportion of patients who will progress to invasive
cancer may be inadequate.
In our study, the results of FNA provided very little insight into
the underlying pathology in this setting. Other studies have high-
lighted limitations in the sensitivity of EUS-FNA in determining
malignancy.6 This compounds the problem of determining the
efficacy of re-operation in this group of patients. Despite this, EUS
remains an important tool in this setting. In addition to its ability
to sample IPMN cells/fluid, the real-time imaging afforded by
EUS often makes it the optimal method by which to characterize
and define any mass or mural nodularity, and differentiate it from










































Figure 2 Kaplan–Meier curves demonstrating no significant differ-
ence in 5-year progression-free survival in (A) patients with known
remnant disease (positive margin and/or radiographically apparent
lesion) and patients without evidence of residual disease, and (B)
patients with radiographic evidence of residual branch duct disease
and patients without evidence of residual disease. IPMN, intraductal
papillary mucinous neoplasm
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dependent cyst mucin and debris. Furthermore, aspiration allows
for cyst fluid to be sent for cytopathology, and the analysis of
markers including carcinoembryonic antigen (CEA), KRas,mucin
and amylase to aid in the diagnosis of recurrent or de novo IPMN,
as well as molecular analyses to aid in testing for malignancy. For
these reasons, EUS remains an appropriate adjunct in most
patients undergoing surveillance, particularly when they develop
progressive symptoms and/or a significant change on cross-
sectional imaging. Although cytopathology was found to be rela-
tively insensitive in this study, the study sample is small and
cytopathology has shown utility in other studies.12,17–19 Although
not commonly used in the setting of remnant surveillance, endo-
scopic retrograde cholangiopancreatography (ERCP), with or
without pancreatic ductoscopy, may be employed on occasion to
interrogate the main pancreatic duct within the head of the pan-
creas in the setting of a patient who has previously undergone a
distal pancreatectomy. In the setting of pancreaticoduodenec-
tomy, reconstruction of the pancreatic remnant using a pancreat-
icogastrostomy will theoretically allow for more accessibility via
ERCP. This has not been particularly useful in our experience and
therefore we employ an EUS rendezvous procedure when ERCP
access to the pancreaticojejunostomy is complicated.
Of the nearly 200 patients in this series, roughly one-fifth had
known residual disease after pancreatic resection and fewer than
half of these had a positive margin. The only patient to develop an
invasive lesion in this subgroup was the patient with residual
low-grade dysplasia involving the main pancreatic duct at the
surgical margin. This provides further support for the conclusion
of several other investigators – that a margin positive for low-
grade IPMN is not an indication for re-resection – but highlights
the exception whereby margin-positive disease that involves the
main duct may present additional risk for the future development



















A Low grade None Non-diagnostic 61 175a Abdominal pain R0; curative resection
B High grade (CIS) None Adenocab 20 31 None Inoperable because of
distant metastasis
C High grade (CIS) None Benign IPMN 99 132 Abdominal Inoperable because of
local invasion
D High grade (CIS) Margin +
low grade
Non-diagnostic 36 62a Recurrent
pancreatitis
R1; vascular invasion
aPatient remains alive at current follow-up
bFNA was performed in an omental lesion





















Figure 3 Similar rates of 5-year progression-free survival were
observed in patients with no residual disease who developed a new
radiographically visible lesion during follow-up and those who
remained free of new lesions






Time to new lesion development,
months, median (range)
33 (7–145) 60 (20–99)
FNA/biopsy/cytology, n (%) 17 (59) 3 (100)
Pathology, n (%)
Acellular/non-diagnostic 5 (29) 1 (33)
Cellular/Scant mucin 5 (29) 0
Low-grade IPMN/mucin 6 (35) 1 (33)
High-grade atypia 1 (6) 1 (33)





High-grade (CIS) 2 –
Invasive – 1
aOne patient developed an additional new intraductal papillary mucinous
neoplasm following re-resection
CIS, carcinoma in situ
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of cancer.6–8 Our findings confirm the practice of not pursuing
significant extensions of pancreatic resection, particularly total
pancreatectomy, in order to achieve a completely negative margin
when low-grade IPMN is present. Further, our data confirm the
practice of extended resection whenever feasible in order to
achieve a clear margin if the main pancreatic duct is involved.
Although the role of operative margins in IPMN has been pre-
viously examined, very few data exist on the impact of residual
radiologic disease in the pancreatic remnant.We noted 30 patients
in whom lesions apparent on radiography and suspicious for
IPMN remained within the residual pancreas. This group demon-
strated 5-year progression-free survival similar to that in patients
without residual IPMN and none of them went on to develop
invasive cancer. This suggests an extremely indolent clinical course
in these patients and would support the practice of not pursuing
total pancreatectomy in patients with multi-centric disease that
appears to be low risk based on clinical and radiologic features,
but, rather, of targeting the highest-risk lesions for segmental
resection.
Importantly, the initial IPMN resection pathology in our study
may be important in predicting the risk for subsequent de novo
invasive cancer development. Three of 29 (10%) patients with
high-grade dysplastic IPMNs at initial segmental resection devel-
oped invasive cancer on follow-up; thus, high-grade dysplasia at
initial resection may confer an increased risk for the subsequent
development of de novo invasive IPMN, even in the setting of
complete clearance on initial resection.
The overall risk for progression to invasive cancer in this series
was very low. Only four patients went on to develop invasive
cancer during surveillance of their pancreatic remnant. We dem-
onstrated a 2% overall risk for the development of invasive cancer
at 5 years of follow-up. The average interval from initial surgery to
the development of new invasive lesions was 54 months (range:
20–99 months). Further, three (75%) of these patients demon-
strated significant symptoms consistent with pancreatic disease.
Given the low risk for developing de novo invasive IPMN and the
substantial disease-free interval until the detection of new invasive
lesions, we would cautiously suggest that reliance on clinical
follow-up combined with less aggressive radiologic surveillance
may be appropriate in selected patients.
Although we feel our data support the conclusions reported
here, we must note several important limitations to this analysis.
Firstly, this represents a retrospective analysis conducted over a
significant period of time. Although the majority of patients were
followed using a standardized clinical algorithm, there was some
variability in the surveillance approach, as well as in the initial
operative approach.
Despite the large number of initial operations for IPMN, rela-
tively few patients underwent re-resection to completion pancre-
atectomy, which renders statistical analysis in this subgroup
challenging as a result of its small size.Mean overall follow-up was
41 months in patients with known residual disease; therefore we
did not achieve the 5-year follow-up mark in this subgroup. In
addition, because of the indolent nature of IPMN, the surveillance
period in this study may render longterm conclusions about the
natural history of this disease somewhat limited.
Additionally, the availability and resolution of cross-sectional
imaging have improved substantially over time. It is likely that
some of the patients whose records date from the earlier period of
this study and who were considered to have no evidence of
residual disease may have harboured very small cystic lesions
which might have been identified with more advanced imaging
(e.g. magnetic resonance imaging or magnetic resonance cholan-
giopancreatography). In other words, lesions described as ‘new’
may actually represent ‘newly discovered’ lesions. These improve-
ments in the quality of imaging will only increase the amount of
lesions discovered. This further highlights the importance of
determining an efficient surveillance schedule for patients with
known residual radiographic disease.
This series provides evidence that complete clearance of IPMN,
by removal of all radiographic lesions, although optimal in focal
Table 6 A comparison of preoperative cytopathology in patients






Not performed, n (%) 3 (27) –
Acellular/non-diagnostic, n (%) 1 (9) 2 (100)
Cellular/scant mucin, n (%) 2 (18) –
Low-grade IPMN/mucin, n (%) 5 (45) –
High-grade dysplasia, n (%) – –
IPMN, intraductal papillary mucinous neoplasm




Symptoms Radiographic features of concern
No IPMN, n (%) 4 (31) 3 1
Low-grade, n (%) 5 (38) 3 3
High-grade (CIS), n (%) 2 (15) 1 2
Invasive, n (%) 2 (15) 2 2
aTwo patients underwent two re-resections each
CIS, carcinoma in situ
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disease, may not be requisite in the setting of low-risk, multi-
centric disease. Our study also further confirms the practice of
avoiding extended resections in the setting of low-grade IPMN
present at the margin that does not involve the main duct. Excep-
tions to this include multi-centric, high-risk lesions and invasive
IPMN.
The oncologic risk to patients with non-invasive IPMN
(without a positive high-grade margin) for developing invasive
IPMN is < 2% in the first 4–5 years following surgery. This finding
holds even in the setting of margins positive for low-grade dys-
plasia and in patients with radiographic evidence of IPMN within
the pancreatic remnant. Furthermore, if imaging detects a new
IPMN in the residual pancreas, 5-year progression-free survival is
not decreased in these patients compared with those without new
lesions.
In conclusion, in the face of non-invasive pathologic or radio-
graphic residual disease following segmental pancreatectomy, the
overall risk for progression to invasive cancer is low. Leaving low-
grade IPMN at the margins or radiographically low-risk IPMN in
the remnant does not substantially increase the risk for the devel-
opment of invasive cancer compared with complete clearance of
pathologically or radiographically detectable disease. In patients
with no residual pancreatic remnant disease, the development of
new radiographic lesions increases the risk for developing invasive
disease. Three of the 31 (9%) patients in this study who developed
new radiographic lesions went on to develop new invasive disease
within 5 years. Thus, these patients may represent a high-risk
subgroup that may need to be followed more closely. In addition,
10% of patients with high-grade dysplastic IPMN at initial seg-
mental resection developed invasive cancer on follow-up; hence
high-grade dysplasia at initial resection may confer an increased
risk for the subsequent development of de novo invasive IPMN.
Although it is important, the accuracy of cytopathology remains
low in the setting of residual IPMN in the pancreatic remnant and
thus cytopathology alone should not be relied upon to guide the
decision of whether or not to operate. This experience highlights
the importance of obtaining a thorough clinical history and
examination, and suggests that more frequent imaging might be
reserved for patients with: (i) newly developed cysts in the pan-
creatic remnant (particularly if the patient is symptomatic); (ii)
high-grade dysplasia on initial resection pathology, or (iii) main
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